Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathieu Pankert

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
International Journal of Cardiology|May 7, 2013
Off-label use of prasugrel in stable coronary artery disease is associated with greater degree of platelet inhibition compared with use after acute coronary syndromeThomas Cuisset, Guillaume Cayla, Jacques Quilici, et al.
International Journal of Cardiology|August 18, 2014
Effectiveness of switching 'low responders' to prasugrel to ticagrelor after acute coronary syndromeClémence Bassez, Pierre Deharo, Mathieu Pankert, et al.
International Journal of Cardiology|August 7, 2013
Effectiveness of switching 'hyper responders' from Prasugrel to Clopidogrel after acute coronary syndrome: the POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH studyPierre Deharo, Coline Pons, Mathieu Pankert, et al.
International Journal of Cardiology|November 16, 2013
Prasugrel versus ticagrelor in acute coronary syndrome: a randomized comparisonPierre Deharo, Clemence Bassez, Guillaume Bonnet, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|February 22, 2016
How should I treat refractory cardiogenic shock in a patient with chronic biventricular heart failure and mitral regurgitation with difficult valve characteristics?Erwan Salaun, Mathieu Pankert, Gilbert Habib, et al.
The American Journal of Cardiology|August 2, 2011
Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndromeThomas Cuisset, Jacques Quilici, William Cohen, et al.
JACC. Cardiovascular Interventions|August 24, 2013
Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs)Thomas Cuisset, Charlotte Grosdidier, Anderson Diendonné Loundou, et al.
American Heart Journal|September 1, 2023
Rationale and design of the ULYSS trial: A randomized multicenter evaluation of the efficacy of early Impella CP implantation in acute coronary syndrome complicated by cardiogenic shockClement Delmas, Marc Laine, Guillaume Schurtz, et al.
The American Journal of Cardiology|November 5, 2013
Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stentingMathieu Pankert, Jacques Quilici, Anderson Diendonné Loundou, et al.
The American Journal of Cardiology|January 24, 2013
Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complicationsCharlotte Grosdidier, Jacques Quilici, Marie Loosveld, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
International Journal of Cardiology|May 7, 2013
Off-label use of prasugrel in stable coronary artery disease is associated with greater degree of platelet inhibition compared with use after acute coronary syndromeThomas Cuisset, Guillaume Cayla, Jacques Quilici, et al.
International Journal of Cardiology|August 18, 2014
Effectiveness of switching 'low responders' to prasugrel to ticagrelor after acute coronary syndromeClémence Bassez, Pierre Deharo, Mathieu Pankert, et al.
International Journal of Cardiology|August 7, 2013
Effectiveness of switching 'hyper responders' from Prasugrel to Clopidogrel after acute coronary syndrome: the POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH studyPierre Deharo, Coline Pons, Mathieu Pankert, et al.
International Journal of Cardiology|November 16, 2013
Prasugrel versus ticagrelor in acute coronary syndrome: a randomized comparisonPierre Deharo, Clemence Bassez, Guillaume Bonnet, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|February 22, 2016
How should I treat refractory cardiogenic shock in a patient with chronic biventricular heart failure and mitral regurgitation with difficult valve characteristics?Erwan Salaun, Mathieu Pankert, Gilbert Habib, et al.
The American Journal of Cardiology|August 2, 2011
Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndromeThomas Cuisset, Jacques Quilici, William Cohen, et al.
JACC. Cardiovascular Interventions|August 24, 2013
Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs)Thomas Cuisset, Charlotte Grosdidier, Anderson Diendonné Loundou, et al.
American Heart Journal|September 1, 2023
Rationale and design of the ULYSS trial: A randomized multicenter evaluation of the efficacy of early Impella CP implantation in acute coronary syndrome complicated by cardiogenic shockClement Delmas, Marc Laine, Guillaume Schurtz, et al.
The American Journal of Cardiology|November 5, 2013
Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stentingMathieu Pankert, Jacques Quilici, Anderson Diendonné Loundou, et al.
The American Journal of Cardiology|January 24, 2013
Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complicationsCharlotte Grosdidier, Jacques Quilici, Marie Loosveld, et al.
Pageof 4